Atom Investors’s NovoCure NVCR Stock Holding History

Atom Investors’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-13,740	Closed	-$178K	–	741
2025 Q3	$178K	Buy	+13,740	New	+$184K	0.01%	521

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

QCM

Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Atom Investors's NVCR Position: Q4 2025 in Review

Atom Investors sold out of NovoCure (NVCR) in Q4 2025, closing a stake of 13,740 shares — an estimated $178K sold.

Atom Investors first reported a position in NVCR in Q3 2025 and held it in 1 quarter. The position peaked at $178K in Q3 2025. 238 funds tracked by Wall St. Rank hold NVCR as of Q4 2025.

Atom Investors reported no remaining NovoCure position as of Q4 2025 after selling out during the quarter.
Atom Investors sold 13,740 NovoCure shares in Q4 2025, an estimated $178K.
Atom Investors first reported a position in NovoCure in Q3 2025 and held it in 1 quarter.
Atom Investors's NovoCure position peaked at $178K in Q3 2025.
238 funds tracked by Wall St. Rank held NovoCure as of Q4 2025.

Based on Atom Investors's 13F filing for Q4 2025, filed 17 Feb 2026.